[go: up one dir, main page]

CN1069522C - 用于防止不希望的宫缩的硝化甘油经皮给药 - Google Patents

用于防止不希望的宫缩的硝化甘油经皮给药 Download PDF

Info

Publication number
CN1069522C
CN1069522C CN95191680A CN95191680A CN1069522C CN 1069522 C CN1069522 C CN 1069522C CN 95191680 A CN95191680 A CN 95191680A CN 95191680 A CN95191680 A CN 95191680A CN 1069522 C CN1069522 C CN 1069522C
Authority
CN
China
Prior art keywords
nitroglycerine
commodity
nitroglycerin
uterine contraction
plaster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN95191680A
Other languages
English (en)
Other versions
CN1140990A (zh
Inventor
H·M·沃尔夫
D·沙特
M·菲利施
B·兰塞
J·F·马丁
C·C·李斯
A·J·迪贝尔达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of CN1140990A publication Critical patent/CN1140990A/zh
Application granted granted Critical
Publication of CN1069522C publication Critical patent/CN1069522C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及硝化甘油以一种经皮使用形式的药用,硝化甘油也称作甘油三硝酸酯,化学命名为1,2,3-丙三醇三硝酸酯,所述的应用是防止妊娠的哺乳动物不希望的宫缩。所述药用预防早产。

Description

用于防止不希望的宫缩的硝化甘油经皮给药
本发明涉及硝化甘油的应用,它用于生产以经皮使用形式用于防止哺乳动物不希望的宫缩的药物。
硝化甘油也称为甘油三硝酸酯(GTN),是一种很久以前人们就熟悉的具有多种用途的化学物质。GTN的化学命名为1,2,3-丙三醇三硝酸酯。硝化甘油尤其是一种名贵的用于治疗冠心病的高效物质。基于这种意义,现在有许多医药工业方案可使用。这种物质的盖伦氏制剂目前包括片剂、胶囊、软膏、注射液、喷雾剂和用于经皮使用的有效物质的膏药。
意外地发现,硝化甘油以经皮应用形式使用时可以防止哺乳动物的不希望宫缩。
对于动物和人的研究表明,通过硝化甘油的盖伦氏制剂形式,对每批研究对象有针对性的使用硝化甘油可以中止宫缩。
下面以对人进行的研究,对本发明作进一步阐述。
研究包括18名怀孕的妇女,她们总是出现提前宫缩。她们的怀孕期已经是怀孕后期,因为她们已经怀孕25和34周之间。她们总是使用GTN膏代替利托君,后者是一种宫缩抑制的有效物质。全部怀孕者表现如下特征:
-胎膜囊还没有破裂;
-没有过早地出血;
-胎儿没有表现出异常。
病人每天接受至多2个GTN膏药,相当于10及10.8mg 1,2,3-丙三醇三硝酸酯。膏药的面积当用DEPONIT10时为32cm2,当用Fa.SCHWARZPHARMA AG产的一种新型的GTN膏药时为16cm2。后者含有硝化甘油,其粘接材料以交联的丙烯酸酯-乙酸乙烯酸共聚物为基础。
两种膏药的使用结果没有差别。两种膏药可防止过早的宫缩、中止过早的宫缩以及停止不规则的宫缩。
表1和2表明,在经皮使用的盖伦氏制剂中的硝化甘油防止怀孕哺乳动物不希望的过早宫缩。
从表可知,使用膏药以后宫缩将被中止。病人当中没有人发生不希望的早产。经根据剂量给予含有硝化甘油的膏药,可以中止剧烈的宫缩或控制不规则的宫缩,直至所希望的产期。
实施例1膏药的制法如同EP 0144486 B1中的实施例1所详细描述的方法。
本发明所述的药物产品具有三层储存结构,按下列方法制备:
一种含有硝化甘油的粘附材料由以下组分制备:
0.175kg聚异丁烯(平均分子量为900,000至1,400,000,商品为OPPANOLB100),
0.157kg固体的脂肪族碳氢化合物树脂(商品为PICCOTAC CBHT),
0.157kg氢化的松香树脂(商品为ABITOL),
0.0105kg 5%硝化甘油在一种中等链长的甘油三酸酯中的溶液(商品为MIGLYOL-812),
1.174kg特种汽油80-110,作为溶剂。
该产物将涂在一个一面用铝镀膜另一面具有粘附性的保护膜上,当溶剂挥发以后得到大约20g/m2的涂层。在这个得到的粘附层上贴上单位面积重量为大约20g/m2的第一个储存层。
储存层的制备是通过沉积一种分散体而完成的,该分散体的组成如下:
0.05kg10%(G/G)的硝化甘油-乳糖研磨物,
0.153kg聚异丁烯(平均分子量为900,000-1,400,000,商品名为OPPANOLB100)
0.137kg固体的脂肪族碳氢化合物树脂(商品名为PICCOTAC CBHT),
0.137kg氢化的松香树脂(商品名为ABITOL)
0.01kg甘油三酸酯,作为溶剂(商品名为MIGLYOL812),
1.148kg特种汽油80-110,作为溶剂。
该产物将沉积在一个分离纸(Trennpapier)上,然后分散体溶剂被挥发掉。
用同样方法将制备一个单位面积重量为大约50g/m2的第二个储存层,其组分为:
0.6kg10%(G/G)硝化甘油-乳糖研磨物,
0.2kg固体的脂肪族碳氢化物树脂(商品名为PICCOTAC CBHT),
0.2kg氢化的松香树脂(商品名为ABITOL),
0.025kg甘油三酸酯,作为溶剂(商品名为MIGLYOL812),
1.876kg特种汽油80-110,作为溶剂,
将第二个储存层贴在第一个储存层上。
用同样的方法由以下组分制备第三个储存层:
2.5kg10%(G/G)硝化甘油-乳糖研磨物,
0.657kg聚异丁烯(平均分子量为900,000-1,400,000;商品名为OPPANOLB100),
0.77kg固体的脂肪族碳氢化物树脂(商品名为PICCOTAC CBHT),
0.77kg氢化的松香树脂(商品名为ABITOL),
7.507kg特种汽油80-110,作为溶剂。
其中,为了达到单位面积重量为大约200g/m2,分散体在分离纸上的沉积要经过三次相继的步骤才能实现。如此得到的第三层储存层被贴在第二层储存层上。
用同样的方法,由下列组分制备单位面积重量为大约20g/m2的粘附中间层:
0.179kg聚异丁烯(平均分子量为900,000-1,400,000;商品名为OPPANOLRB100),
0.16kg固体的脂肪族碳氢化物树脂(商品名为PICCOTAC CBHT),
0.16kg氢化的松香树脂(商品名为ABITOL)。
1.167kg特种汽油80-110,作为溶剂。
将粘附中间层贴在第三层储存层上。
粘附中间层用一种不透气的覆盖膜盖上以后,得到的层状物将按治疗的要求分割成单一的小块。
硝化甘油-膏药具有以下结构:它是一个矩形体系,由一个多层构造的、充满药物的接触膜,由聚异丁烯、固体的脂肪族碳氢化物树脂和氢化的松香树脂构成,最外层由一个聚酯薄膜覆盖上。一个32cm2的膏药含有32mg硝化甘油。有效物质在皮肤上的平均释放量为10mg/24小时。经皮体系的释放表面将用一个硅化处理的和金属镀膜的聚酯薄膜保护起来,在使用之前再将此膜揭掉。
实施例2
膏药的制备方法如PCT/EP 92/01169=WO 92/22292 A1中的实施例3所详细描述的那样。
这种硝化甘油-膏药具有以下构造:它是一个矩形体系,它是由一个含有硝化甘油的、由一种交联的丙烯酸酯-乙酸乙烯酯共聚物为基础的粘附材料构成,最外层由一种聚酯薄膜所覆盖。
这种16cm2的膏药含有40mg硝化甘油。有效物质对皮肤的平均释放量为10.8mg/24小时。这种经皮体系的释放表面用一种聚酯薄膜保护起来,在使用之前再把它揭掉。
表1
子宫颈膨胀 妊娠期 宫缩 用Deponit1010mg TN 宫缩终止
5cm  32周 每3分钟收缩2次 每日同时2剂 3小时之内.+
4cm  32周 每3分钟收缩1次 每日同时2剂 3小时之内.+
2cm  25周 不规则 每日用1剂 5小时之内.+
表2
子宫颈膨胀 妊娠期 宫缩 用GTN-丙烯酸酯膏药10.8mg GTN 宫缩终止
5cm  32周 每3分钟收缩2次 每日同时2剂 3小时之内.+
4cm  32周 每3分钟收缩1次 每日同时服2剂 3小时之内.+
2cm  25周 不规则 每日用1剂 5小时之内.+

Claims (2)

1.1,2,3-丙三醇三硝酸酯用于生产以一种经皮使用形式用于防止哺乳动物不希望的宫缩的药物的应用。
2.1,2,3-丙三醇三硝酸酯用于生产以一种经皮使用形式用于防止哺乳动物早产的药物的应用。
CN95191680A 1994-02-28 1995-02-23 用于防止不希望的宫缩的硝化甘油经皮给药 Expired - Fee Related CN1069522C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4406332.6 1994-02-28
DE4406332A DE4406332C1 (de) 1994-02-28 1994-02-28 Pharmazeutische Verwendung von Nitroglycerin zur Verhinderung unerwünschter Wehentätigkeit bei Säugern in einer transdermalen Applikationsform

Publications (2)

Publication Number Publication Date
CN1140990A CN1140990A (zh) 1997-01-22
CN1069522C true CN1069522C (zh) 2001-08-15

Family

ID=6511303

Family Applications (1)

Application Number Title Priority Date Filing Date
CN95191680A Expired - Fee Related CN1069522C (zh) 1994-02-28 1995-02-23 用于防止不希望的宫缩的硝化甘油经皮给药

Country Status (15)

Country Link
US (1) US5817697A (zh)
EP (1) EP0804176B1 (zh)
JP (1) JP2823700B2 (zh)
KR (1) KR100334372B1 (zh)
CN (1) CN1069522C (zh)
AT (1) ATE200732T1 (zh)
CA (1) CA2184201A1 (zh)
DE (2) DE4406332C1 (zh)
DK (1) DK0804176T3 (zh)
ES (1) ES2156938T3 (zh)
FI (1) FI963329A (zh)
GR (1) GR3035785T3 (zh)
NO (1) NO961724L (zh)
PT (1) PT804176E (zh)
WO (1) WO1995022964A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020015951A1 (en) * 2000-01-06 2002-02-07 Bader Joel S. Method of analyzing a nucleic acid

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306503A (en) * 1990-06-25 1994-04-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch with a high content of softening ingredients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU560710B2 (en) * 1983-04-27 1987-04-16 Lohmann Gmbh & Co. Kg. Pharmaceutical product
US5498418A (en) * 1991-06-10 1996-03-12 Schwarz Pharma Ag Nitroglycerine plaster and process for its production
US5508045A (en) * 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy
JPH1192367A (ja) * 1997-09-22 1999-04-06 Hoechst Marion Roussel Kk 妊娠悪阻治療剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306503A (en) * 1990-06-25 1994-04-26 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch with a high content of softening ingredients

Also Published As

Publication number Publication date
FI963329A0 (fi) 1996-08-27
CA2184201A1 (en) 1995-08-31
EP0804176A1 (de) 1997-11-05
PT804176E (pt) 2001-08-30
NO961724D0 (no) 1996-04-29
FI963329A (fi) 1996-09-05
DE59509223D1 (de) 2001-05-31
JP2823700B2 (ja) 1998-11-11
WO1995022964A1 (de) 1995-08-31
CN1140990A (zh) 1997-01-22
US5817697A (en) 1998-10-06
ATE200732T1 (de) 2001-05-15
JPH09506108A (ja) 1997-06-17
GR3035785T3 (en) 2001-07-31
KR100334372B1 (ko) 2002-09-04
NO961724L (no) 1996-04-29
DK0804176T3 (da) 2001-05-28
ES2156938T3 (es) 2001-08-01
KR960705553A (ko) 1996-11-08
DE4406332C1 (de) 1995-06-22
EP0804176B1 (de) 2001-04-25

Similar Documents

Publication Publication Date Title
CN1111402C (zh) 曲马多的多剂量单位制剂
KR101471216B1 (ko) 높은 비율의 활성 성분 이용률 및 투약 정확도를 갖는 경피 치료 시스템
EP2494966B1 (en) Stable composition of rasagiline
JPS61155321A (ja) 経皮貼剤及びその製造方法
CN1708292A (zh) 药物口服速溶膜
KR20020058008A (ko) 약리학적으로 활성이 있는 또는 다른 물질의 2상 방출용필름 형태의 약제
EP0593807A1 (en) Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
CN102548546A (zh) 用于施用芬太尼或其类似物的透皮治疗系统
CN1087938C (zh) 东莨菪碱膏药
JP2003533434A (ja) 改良された経皮的避妊薬送達系および方法
CN1226152A (zh) 用于治疗早老性痴呆的透皮丙戊茶碱组合物
EP0144486B1 (en) Controlled-release drugsystem and process for preparing it
CN1069522C (zh) 用于防止不希望的宫缩的硝化甘油经皮给药
EP0306926A2 (en) Salbutamol-containing plaster and method of producing
CN1348371A (zh) 沙利度坦及其可药用的盐在制造用于治疗和预防情绪障碍、适应能力障碍或焦虑-抑郁混合病症总体上的药物方面的应用
US6277400B1 (en) Extendible transdermal therapeutic system
WO2001010420A1 (en) Transdermal patch comprising methylphenidate
CN1149087C (zh) 内皮素拮抗剂和β-受体阻滞剂的组合制剂
FR2749586A1 (fr) Nouveaux dispositifs destines a l'administration transdermique de la trimegestone, leur procede de preparation et leur application a titre de medicaments
CN1615857A (zh) 氨来呫诺双层口腔粘附片及其制备方法
CN106890166A (zh) 含有钙受体活性化合物的皮肤外用制剂
CN1258363C (zh) 尼莫地平贴片
CN113677343A (zh) 生物体对药物的吸收性优异且化学稳定性也优异的医药组合物
CN1226163A (zh) 治疗和/或预防痴呆的制剂
CN1633995A (zh) 一种透皮避孕药传送体系及方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee